{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:26:57Z","timestamp":1793852817802,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jclinepi.2026.112465","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:50:51Z","timestamp":1786690251000},"page":"112465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6941-730X","authenticated-orcid":false,"given":"Arthur","family":"Gougeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-8618","authenticated-orcid":false,"given":"Emmanuel","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudina","family":"Michal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Rabilloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-9972","authenticated-orcid":false,"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-0346","authenticated-orcid":false,"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Boussageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-2581","authenticated-orcid":false,"given":"Guillaume","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2968","authenticated-orcid":false,"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2026.112465_bib1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.12688\/f1000research.26707.2","article-title":"The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days","volume":"9","author":"Janiaud","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.jclinepi.2026.112465_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jclinepi.2026.112465_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2026.112465_bib4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/cts.13591","article-title":"Totality of evidence of the effectiveness of repurposed therapies for COVID-19: can we use real-world studies alongside randomized controlled trials?","volume":"16","author":"Mandema","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jclinepi.2026.112465_bib5","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for COVID-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2026.112465_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jclinepi.2026.112465_bib7","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in late-stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jclinepi.2026.112465_bib8","first-page":"447","article-title":"Parsing clinical success rates","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jclinepi.2026.112465_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40656-022-00532-9","article-title":"The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence","volume":"44","author":"Maziarz","year":"2022","journal-title":"HPLS"},{"key":"10.1016\/j.jclinepi.2026.112465_bib10","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1001\/jama.1987.03390180077027","article-title":"Are all significant P values created equal? The analogy between diagnostic tests and clinical research","volume":"257","author":"Browner","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112465_bib11","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.jclinepi.2026.112465_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2026.112465_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1081\/BIP-120006450","article-title":"Reconsidering some aspects of the two-trials paradigm","volume":"12","author":"Maca","year":"2002","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.jclinepi.2026.112465_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2026.112465_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jnci\/djh075","article-title":"Assessing the probability that a positive report is false: an approach for molecular epidemiology studies","volume":"96","author":"Wacholder","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2026.112465_bib18","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2026.112465_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pst.2262","article-title":"Should the two-trial paradigm still be the gold standard in drug assessment?","volume":"22","author":"Zhan","year":"2023","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jclinepi.2026.112465_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41562-017-0189-z","article-title":"Redefine statistical significance","volume":"2","author":"Benjamin","year":"2018","journal-title":"Nat Hum Behav"},{"key":"10.1016\/j.jclinepi.2026.112465_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41562-016-0021","article-title":"A manifesto for reproducible science","volume":"1","author":"Munaf\u00f2","year":"2017","journal-title":"Nat Hum Behav"},{"key":"10.1016\/j.jclinepi.2026.112465_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0840470415581251","article-title":"A discussion of the ethical implications of random drug testing in the workplace","volume":"28","author":"Christie","year":"2015","journal-title":"Healthc Manage Forum"},{"key":"10.1016\/j.jclinepi.2026.112465_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jama.2020.13319","article-title":"Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomized harmony","volume":"324","author":"Califf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112465_bib25","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.7861\/fhj.2021-0083","article-title":"Making trials part of good clinical care: lessons from the RECOVERY trial","volume":"8","author":"Pessoa-Amorim","year":"2021","journal-title":"Future Healthc J"},{"key":"10.1016\/j.jclinepi.2026.112465_bib26","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.eclinm.2022.101362","article-title":"Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group","volume":"46","author":"Hermine","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jclinepi.2026.112465_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112465_bib28","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/S1473-3099(23)00455-3","article-title":"Overcoming publication and dissemination bias in infectious diseases clinical trials","volume":"24","author":"Grobusch","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:04:47Z","timestamp":1793851487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626003410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"alternative-id":["S0895435626003410"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112465","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112465"}}